5. Progressive supranuclear palsy Clinical trials / Disease details
Clinical trials : 95 / Drugs : 119 - (DrugBank : 40) / Drug target genes : 65 - Drug target pathways : 108
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05005819 (ClinicalTrials.gov) | May 25, 2021 | 29/6/2021 | Evaluation of [18F]APN-1607 as a PET Biomarker | Evaluation of [18F]APN-1607 as a PET Biomarker for Longitudinal Change in Tau Pathology in Participants With Progressive Supranuclear Palsy | Progressive Supranuclear Palsy;Healthy Volunteers | Drug: [18F] APN-1607 | Invicro | NULL | Recruiting | 50 Years | 80 Years | All | 18 | Phase 1 | United States |